Posts

Recent BPSI trend: biopharma sentiment improving from pessimism to cautious optimism

on

Novartis may cut around 130 jobs in Switzerland while relocating biologics production

on

AbbVie’s T-cell engager shows survival benefit in Phase 3 multiple myeloma study

on

Pfizer Licenses Out Another Seagen ADC, Raising Fresh Questions About $43 Billion Deal

on

Novartis’ Rhapsido shows positive Phase 3 MS results, intensifying Roche competition

on

Pfizer licenses discontinued ADC to Medicus as Revolution Medicines updates lung-cancer data

on

China reportedly approves first AI-assisted innovative drug for marketing

on

Three takeaways from the latest White House drug-pricing event

on

GSK to license Hutchmed cancer drug for $110 million upfront

on

AbbVie reports Phase 3 multiple-myeloma win, positioning etentamig for a competitive BCMA market

on

Ultragenyx’s Angelman Phase 3 Miss Triggers Review and Cost-Cutting

on

Why Roche is excited about Hanmi’s muscle-sparing obesity drug

on

FDA files show lingering concerns and split views over Replimune’s melanoma drug

on